Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing antibiotic tolerance using low dose nitric oxide in cystic fibrosis pulmonary exacerbations
2010-023529-39Phase 2Terminated
- Sponsor
- University Hospital Southampton
- Start
- Dec 2010
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of nitric oxide in cystic fibrosis (CF), sponsored by University Hospital Southampton. Primary endpoint: Change in proportion of Pseudomonas aeruginosa bacteria in biofilms. Started Dec 2010; status: terminated.
02
Drugs
nitric oxide
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2010-023529-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023529-39.